Clearstead Advisors’s Chemours CC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.48K Buy
121
+55
+83% +$1.26K ﹤0.01% 2403
2026
Q1
$1.45K Sell
66
-1
-1% -$17 ﹤0.01% 1966
2025
Q4
$790 Buy
67
+1
+2% +$13 ﹤0.01% 2255
2025
Q3
$1.05K Hold
66
﹤0.01% 2607
2025
Q2
$756 Hold
66
﹤0.01% 2458
2025
Q1
$893 Buy
+66
New +$1.1K ﹤0.01% 1999
2024
Q3
Sell
-68
Closed -$1.53K 2050
2024
Q2
$1.53K Hold
68
﹤0.01% 1847
2024
Q1
$1.95K Hold
68
﹤0.01% 1315
2023
Q4
$2.15K Sell
68
-136
-67% -$3.69K ﹤0.01% 1276
2023
Q3
$5.72K Buy
204
+70
+52% +$2.4K ﹤0.01% 1211
2023
Q2
$4.94K Buy
+134
New +$4.09K ﹤0.01% 1051
2023
Q1
Sell
-126
Closed -$3.86K 1375
2022
Q4
$3.86K Buy
126
+60
+91% +$1.8K ﹤0.01% 1009
2022
Q3
$2K Hold
66
﹤0.01% 1071
2022
Q2
$2K Buy
+66
New +$2.43K ﹤0.01% 1096
2021
Q4
Sell
-920
Closed -$27K 1293
2021
Q3
$27K Buy
920
+800
+667% +$25.9K ﹤0.01% 721
2021
Q2
$4K Buy
+120
New +$3.97K ﹤0.01% 908
2020
Q2
Sell
-40
Closed 790
2020
Q1
$0 Buy
+40
New +$577 ﹤0.01% 772

Other funds holding CC

Clearstead Advisors's CC Position: Q2 2026 in Review

Clearstead Advisors increased its Chemours (CC) stake by 83% in Q2 2026, buying an estimated $1.26K and bringing the position to 121 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2403.

Clearstead Advisors first reported a position in CC in Q1 2020 and has held it in 17 quarters since. The position peaked at $27K in Q3 2021. 470 funds tracked by Wall St. Rank hold CC as of Q2 2026.

  • Clearstead Advisors held 121 shares of Chemours worth $2.48K as of Q2 2026.
  • Clearstead Advisors bought 55 Chemours shares in Q2 2026, an estimated $1.26K.
  • Chemours made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2403 holding.
  • Clearstead Advisors first reported a position in Chemours in Q1 2020 and has held it in 17 quarters since.
  • Clearstead Advisors's Chemours position peaked at $27K in Q3 2021.
  • 470 funds tracked by Wall St. Rank held Chemours as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.